• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Bacterial Conjunctivitis - Pipeline Review, H2 2012 Product Image

Bacterial Conjunctivitis - Pipeline Review, H2 2012

  • Published: December 2012
  • 33 pages
  • Global Markets Direct

Bacterial Conjunctivitis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Bacterial Conjunctivitis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bacterial Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacterial Conjunctivitis. Bacterial Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bacterial Conjunctivitis.
- A review of the Bacterial Conjunctivitis products under development READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Bacterial Conjunctivitis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Bacterial Conjunctivitis 7
Bacterial Conjunctivitis Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Discovery and Pre-Clinical Stage Products 11
Comparative Analysis 11
Bacterial Conjunctivitis Therapeutics – Products under Development by Companies 12
Companies Involved in Bacterial Conjunctivitis Therapeutics Development 13
InSite Vision Incorporated 13
NovaBay Pharmaceuticals, Inc. 14
LABORATOIRES THEA 15
Bacterial Conjunctivitis – Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Drug Profiles 21
azithromycin - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
azithromycin - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
NVC-727 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
NVC-638 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
NVC-704 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
EGP-Antibiotics - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Bacterial Conjunctivitis Therapeutics - Dormant Products 27
Bacterial Conjunctivitis – Product Development Milestones 28
Featured News & Press Releases 28
Nov 08, 2012: Bausch + Lomb To Present Data On Besifloxacin Ophthalmic Suspension At American Academy of Ophthalmology Annual Meeting 28
Jan 05, 2012: University Of California, San Francisco Files Appeal Of USPTO Judgment In Favor Of InSite Vision 28
Nov 28, 2011: InSite Vision Wins Patent Interference Litigation Against University Of California, San Francisco 28
Oct 18, 2010: Garamycin Ophthalmic Ointment Now Available from Fera Pharmaceuticals 29
Sep 22, 2010: Alcon Launches TobraDex ST Suspension In US 29
Dec 17, 2009: NovaBay To Receive Increase In Funding And Support From Alcon 29
Jun 02, 2009: InSite Vision Announces FDA Approval of New Ophthalmic Product Enabled by InSite's DuraSite(R) Technology 30
May 29, 2009: Bausch & Lomb Receives FDA Approval of Besivance, New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis (“Pink Eye”) 30
Dec 05, 2008: FDA Advisory Committee Recommends Approval of Bausch & Lomb Besifloxacin Anti-Infective Eye Drop 31
Jul 19, 2005: Select Access to Co-Promote Allergan's Zymar to Primary Care Physicians. 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables
Number of Products Under Development for Bacterial Conjunctivitis, H2 2012 7
Products under Development for Bacterial Conjunctivitis – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 11
Products under Development by Companies, H2 2012 12
InSite Vision Incorporated, H2 2012 13
NovaBay Pharmaceuticals, Inc., H2 2012 14
LABORATOIRES THEA, H2 2012 15
Assessment by Monotherapy Products, H2 2012 16
Assessment by Stage and Route of Administration, H2 2012 18
Assessment by Stage and Molecule Type, H2 2012 20
Bacterial Conjunctivitis Therapeutics – Dormant Products 27

List of Figures
Number of Products under Development for Bacterial Conjunctivitis, H2 2012 7
Products under Development for Bacterial Conjunctivitis – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 10
Discovery and Pre-Clinical Stage Products, H2 2012 11
Assessment by Monotherapy Products, H2 2012 16
Assessment by Route of Administration, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 18
Assessment by Molecule Type, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 20

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos